GPT-Rosalind (OpenAI) vs Devin

Devin edges out GPT-Rosalind (OpenAI) by 0.6 points (7.4 vs 6.8) -- a B-tier vs C-tier split that's narrow but real. Not a blowout; both belong on a shortlist. The score gap shows up most clearly in the categories that matter for Devin's strengths, so if those categories are your priority, the lead translates.

Neither tool offers a free tier. GPT-Rosalind (OpenAI) starts at Invite only, Devin at $20. Plan to budget for whichever you pick. The cheap tier usually caps out faster than buyers expect, so look at what the entry plan actually includes -- both vendors have raised list prices in 2026 and the limits are where most of the cost surprise lives.

By use case: pick GPT-Rosalind (OpenAI) when researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access. Pick Devin when development teams that want to offload well-scoped tasks like bug fixes, test writing, and boilerplate code to an autonomous agent. The two tools aren't fighting for the same person -- they're aiming at adjacent jobs that occasionally overlap. If you're squarely in Devin's lane, the tier-list ranking and the use-case fit point the same direction; if you're in GPT-Rosalind (OpenAI)'s lane, the score gap matters less than the fit.

Bottom line: Devin is the safer default for most readers, but GPT-Rosalind (OpenAI) is competitive enough that the tie-breaker is your specific workload, not the spec sheet.